BLOCKStrain TECHNOLOGY CORP. (the “Company” or “BLOCKStrain”) (TSXV: DNAX) is pleased to welcome National Green Biomed Ltd. (“NG Biomed” or “NG”) to its software platform.

BLOCKStrain and NG Biomed this week signed a Letter of Intent for adoption of the BLOCKStrain software platform at NG Biomed’s production facility in British Columbia, Canada. NG Biomed is a late-stage applicant to become a licensed producer under the Access to Cannabis for Medical Purposes Regulations in Canada.


Under the Letter of Intent signed June 18, 2018, the Parties agree to negotiate the terms of a business relationship through which BLOCKStrain will integrate its core software platform into the operational infrastructure of NG Biomed in order to optimize product testing, genetic verification, supply chain visibility and management of grow operations.

Secondly, BLOCKStrain will use its proprietary technology to create a custom platform for NG Biomed that will empower NG Biomed’s clients and partners with the ability to instantly arrange for sales, shipping, testing and analysis of NG Biomed products, as well as giving comprehensive visibility over such products throughout their entire life cycles.

NG Biomed is currently launching an initial 30,000 square foot greenhouse facility on 68 acres in the Fraser Valley region of BC, and has room to expand to at least 500,000 square feet of production space.

The company is headed by former federal cabinet minister Herb Dhaliwal as Chairman of the Board, and son Justin Dhaliwal as CEO.

BLOCKStrain CEO Robert Galarza says he’s excited and honored to work with an experienced and well connected management team that focuses heavily on research and development.

“Over the past several years, I’ve had the privilege of getting to know Herb and Justin very well, and I believe they are among the most professional and connected people I have met in the cannabis space in the US or Canada,” Galarza says. “Their integrity is second to none and it has been a true pleasure working with them to advance our technology’s data centric solution for this industry.”

NG Biomed CEO Justin Dhaliwal says his company chose to work with BLOCKStrain not just because they were impressed by the software, but because they were impressed by the BLOCKStrain team.

“We feel implementing smart technology allows us to be more efficient, and in terms of record management, we need to keep track of all our strains and genetics in a way that is simple, effective and enforceable,” Dhaliwal said.

“Robert is a great leader and a very insightful businessman, and their CTO Tommy Stephenson is absolutely brilliant,” Dhaliwal added. “Tommy’s experience as the former CTO at WeedMaps is also important. He’s an expert in IT, absolutely, but it’s more important that he really understands the industry’s needs because he’s lived it for so many years.”

The parties to the agreement say they will be working out details of the BLOCKStrain software deployment over the coming weeks, and finalizing the terms within a formal definitive agreement.

ON BEHALF OF THE BOARD OF DIRECTORS
“Robert Galarza”

Robert Galarza
Chief Executive Officer and Director

About BLOCKStrain Technology Corp.

BLOCKStrain Technology Corp. (TSXV: DNAX) has developed the first integrated blockchain platform that registers and tracks intellectual property for the cannabis industry. Strain protection and genetic identification are major issues for growers and breeders, and this new technology allows them to identify and secure rights to their valuable intellectual property (IP). The BLOCKStrain platform also streamlines the administrative process of genetic and mandatory quality-control testing for legal cannabis, cutting the administrative time and expense in half.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information
Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to the expected benefits of, and impact on, NG Biomed’s business as a result of the use of BLOCKStrain’s technology; and the expected security and other benefits of BLOCKStrain’s technology generally. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: BLOCKStrain’s platform may not operate as expected; NG Biomed may not derive the expected benefits from use of the BLOCKStrain platform; legislative changes may occur that negatively impact BLOCKStrain’s business; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

Click here to connect with BLOCKStrain TECHNOLOGY CORP. (TSXV: DNAX) for an Investor Presentation

Source: www.newswire.ca

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less